![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Extrovis Ag Baar Ch, based in Switzerland, is a pharmaceutical company.
They are recognized for Extrovis's success lies in improving healthcare through innovation.
One of their significant offerings is Dapsone, supported by a 'Valid' Certificate of Suitability (CEP) with the number CEP 2022-379 - Rev 00
This Chemical Type CEP, issued on June 12, 2024, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 77 associated with this CEP further emphasizes